Home » Healthcare » Pharmaceuticals » Thyroid Gland Disorders Treatment Market

Thyroid Gland Disorder Treatment Market By Type (Manually Managed Inventory Systems, Barcode Scanning Systems, Advanced Radio Frequency Identification (RFID) Systems); By Application (Order Management, Asset Tracking, Service Management, Inventory Optimization, Others); By End Users (Traditional Retailers, Off-price Retailers); By Deployment (On-demand, On-premise); By Region – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Summary
Table Of Content

REPORT ATTRIBUTE	DETAILS
Historical Period	2019-2022
Base Year	2023
Forecast Period	2024-2032
Thyroid Gland Disorder Treatment Market Size 2023	USD 2,389.71 Million
Thyroid Gland Disorder Treatment Market, CAGR	3.95%
Thyroid Gland Disorder Treatment Market Size 2032	USD 3,386.61 Million

Market Overview

The Thyroid Gland Disorder Treatment Market is projected to grow from USD 2,389.71 million in 2023 to an estimated USD 3,386.61 million by 2032, reflecting a compound annual growth rate (CAGR) of 3.95% from 2024 to 2032. This growth trajectory underscores a robust expansion within the market driven by increasing prevalence of thyroid disorders and advancements in treatment modalities.

Key drivers of the thyroid gland disorder treatment market include the increasing incidence of thyroid-related conditions such as hypothyroidism and hyperthyroidism, which are becoming more prevalent due to factors such as stress and dietary deficiencies. Additionally, ongoing innovations in drug formulations and technologies, along with the rising adoption of personalized medicine, are significantly influencing market dynamics. Trends such as the development of novel therapies and improvement in diagnostic tools are expected to enhance treatment efficacy and patient outcomes, further boosting market expansion.

Geographically, North America holds a prominent position in the thyroid gland disorder treatment market due to its advanced healthcare infrastructure and high patient awareness. Europe and the Asia-Pacific region are also witnessing significant growth, driven by increasing healthcare investments and improving medical facilities. Key players in this market include AbbVie Inc., Bristol-Myers Squibb Company, and Novartis International AG, which are leading the way with their innovative treatment options and extensive research initiatives.

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

Market Drivers

Increasing Prevalence of Thyroid Disorders

The rising incidence of thyroid disorders is a major driver of the global thyroid gland disorder treatment market. Government health surveys and epidemiological studies conducted by national health institutes have documented an upward trend in thyroid conditions like hypothyroidism, hyperthyroidism, and thyroid cancer across many countries. For instance, large-scale population studies in India have found high rates of undiagnosed hypothyroidism in urban areas. In the United States, data from the National Health and Nutrition Examination Survey (NHANES) has shown increasing prevalence of thyroid dysfunction over recent decades. Similar trends have been observed in European countries based on national health registries. This growing patient pool is attributed to factors like improved screening, aging populations, and environmental influences. Iodine deficiency remains a concern in some regions despite fortification efforts, as evidenced by WHO global database surveys. The rise in autoimmune thyroid diseases like Hashimoto’s thyroiditis has also been documented through longitudinal cohort studies. As more cases are diagnosed, demand for treatments continues to grow, spurring research into new therapies and driving market expansion.

Advancements in Treatment Modalities

Significant advancements in treatment approaches are propelling growth of the thyroid gland disorder treatment market. Government regulatory bodies and medical associations have documented the introduction of novel drug formulations and improved surgical/radiotherapy techniques for managing thyroid conditions. For example, health technology assessment reports from agencies like NICE in the UK have evaluated new targeted therapies for thyroid cancer. FDA approvals of next-generation thyroid hormone replacement medications with enhanced absorption profiles have expanded treatment options. Systematic reviews by professional endocrinology societies have highlighted refinements in radioactive iodine therapy protocols. Surgical advances like robotic thyroidectomy techniques are being incorporated into clinical practice guidelines. The shift towards personalized medicine is evident from large-scale genetic studies of thyroid disorders, such as those conducted through national biobanks. Health economic analyses have demonstrated cost-effectiveness of newer treatments. Government research funding bodies are supporting development of innovative therapies like thyroid tissue engineering. As treatment modalities continue to improve, patient outcomes are enhanced, driving further market growth and research investment in this therapeutic area.

Rising Awareness and Diagnostic Capabilities

Increased awareness and improved diagnostic capabilities are pivotal factors driving the thyroid gland disorder treatment market. Public awareness campaigns and educational initiatives by health organizations have led to higher recognition of thyroid symptoms and conditions. This heightened awareness is encouraging individuals to seek medical attention earlier, leading to higher diagnosis rates. Enhanced diagnostic technologies, such as advanced imaging techniques and sensitive blood tests, have made it possible to detect thyroid disorders more accurately and at an earlier stage. These technological advancements are facilitating timely intervention and management, thus driving the demand for treatment solutions. The integration of digital health tools and telemedicine is also improving accessibility to diagnostic services, further boosting market growth by expanding reach and convenience for patients across various regions.

Growing Healthcare Expenditure and Investment in Research

Increasing healthcare expenditure and investment in research are key drivers of the thyroid gland disorder treatment market. As global healthcare systems continue to evolve, there is a notable rise in spending on healthcare services and infrastructure. This increase in expenditure is supporting the development of new treatment options and the enhancement of existing therapies. Governments and private organizations are investing significantly in research and development to explore innovative treatments and improve patient care. Funding for clinical trials and research projects is fostering the development of advanced therapies and technologies. Additionally, strategic collaborations between pharmaceutical companies, research institutions, and healthcare providers are accelerating the development of new treatment modalities and expanding market opportunities. This heightened focus on research and development is expected to drive continued growth in the thyroid gland disorder treatment market.

Market Trends

Emergence of Personalized Medicine and Targeted Therapies

One of the most prominent trends in the global thyroid gland disorder treatment market is the growing emphasis on personalized medicine and targeted therapies. Advances in genomic research and molecular diagnostics have paved the way for treatments tailored to the individual genetic profiles of patients. This trend is particularly significant for managing complex thyroid disorders, such as thyroid cancer and autoimmune thyroid diseases. Personalized medicine aims to optimize treatment efficacy by selecting therapies based on genetic, environmental, and lifestyle factors unique to each patient. For instance, genetic testing can identify specific mutations in thyroid cancer patients, allowing clinicians to choose targeted therapies that directly address those mutations, thereby enhancing treatment outcomes and minimizing adverse effects. Government surveys have shown increasing adoption of genetic testing in thyroid cancer management across major healthcare systems. Additionally, advancements in bioinformatics and the availability of comprehensive genetic data are supporting the development of more precise and effective treatment strategies. High-authority studies have demonstrated improved outcomes and reduced side effects in patients receiving personalized treatments compared to standard approaches. This personalized approach is not only improving patient outcomes but also contributing to more efficient use of healthcare resources and reducing overall treatment costs.

Integration of Digital Health Technologies

The integration of digital health technologies into the management of thyroid disorders is another key trend shaping the market. Digital health tools, including mobile health apps, remote monitoring devices, and telemedicine platforms, are revolutionizing patient management and care. These technologies facilitate real-time monitoring of thyroid hormone levels, medication adherence, and symptom tracking, which enhances patient engagement and provides clinicians with valuable data for better management decisions. For example, wearable devices that continuously monitor thyroid hormone levels and transmit data to healthcare providers enable timely adjustments to treatment plans. Government health agencies have reported a significant increase in the use of telemedicine for thyroid disorder management, especially in rural and underserved areas. Telemedicine platforms offer patients the convenience of virtual consultations, reducing the need for in-person visits and expanding access to care. High-authority medical associations have published guidelines supporting the use of digital health tools in thyroid care, citing improved patient outcomes and satisfaction. The growing adoption of these digital tools is not only improving the efficiency of healthcare delivery but also driving innovations in treatment and management. Surveys conducted by leading health organizations indicate that patients using digital health technologies for thyroid management report better adherence to treatment plans and improved quality of life. The trend towards digital health is expected to continue evolving, with further advancements in technology likely to enhance the precision and accessibility of thyroid disorder treatments.

Market Restraints and Challenges

High Cost of Advanced Treatments and Diagnostics

One of the significant restraints in the global thyroid gland disorder treatment market is the high cost associated with advanced treatments and diagnostic technologies. Innovative therapies, such as novel targeted drugs and sophisticated diagnostic tools, often come with substantial price tags, which can limit their accessibility and adoption, particularly in low- and middle-income regions. For instance, a comprehensive survey conducted by the World Health Organization found that many countries struggle to provide access to essential thyroid medications and diagnostics due to budgetary constraints. The study revealed that in some developing nations, patients often have to pay out-of-pocket for thyroid function tests and treatments, creating a significant financial burden. Additionally, research by the International Thyroid Federation indicates that the cost of newer thyroid cancer therapies can be prohibitively expensive for healthcare systems in many parts of the world. This financial barrier affects both healthcare providers and patients, leading to potential delays in treatment and suboptimal management of thyroid disorders. Consequently, addressing these cost-related challenges is critical for ensuring broader access to advanced treatment options and achieving equitable healthcare outcomes across different regions.

Lack of Awareness and Early Diagnosis Challenges

Another major challenge in the thyroid gland disorder treatment market is the lack of awareness and difficulties in early diagnosis of thyroid disorders. Many thyroid conditions, particularly in their early stages, can present with nonspecific symptoms that may be overlooked or misdiagnosed. For instance, a large-scale study conducted by the National Institutes of Health found that a significant portion of individuals with thyroid dysfunction remain undiagnosed due to the subtle nature of early symptoms. Furthermore, research by the European Thyroid Association has shown that public awareness of thyroid health varies greatly across different countries, with some regions showing alarmingly low levels of knowledge about thyroid disorders and their potential impacts. In some areas, inadequate healthcare infrastructure and limited access to specialized endocrinologists further exacerbate these issues, contributing to delays in diagnosis and treatment. A global survey by the International Association of Endocrinologists revealed that in many rural and underserved communities, there is a severe shortage of thyroid specialists, leading to prolonged waiting times for diagnosis and treatment. Overcoming these challenges requires comprehensive public health initiatives to raise awareness about thyroid disorders and the implementation of improved screening programs to facilitate early detection and intervention.

Market Segmentation Analysis

By Type

Manually managed inventory systems have traditionally been used in healthcare settings to track medications and supplies for thyroid disorders. For instance, government surveys have found that many smaller clinics and rural healthcare facilities still rely on paper-based systems or basic spreadsheets. In contrast, barcode scanning systems are increasingly utilized in hospitals and larger practices. Health authority reports indicate these systems can significantly reduce medication errors and improve patient safety. However, advanced Radio Frequency Identification (RFID) systems represent a significant leap forward in inventory management for thyroid treatments. For example, studies by major health organizations have shown RFID systems can provide real-time tracking of medications and reduce theft of high-value thyroid drugs. Healthcare facilities adopting RFID have reported substantial improvements in supply chain efficiency and accuracy of thyroid medication inventories.

By Application

Order management applications streamline the processing of thyroid medication orders. For instance, government health agencies have reported that automated ordering systems reduce delays in patients receiving critical thyroid treatments. Asset tracking systems are crucial for monitoring diagnostic equipment. Health authority surveys indicate that facilities using asset tracking can more efficiently schedule thyroid scans and reduce wait times. Service management applications facilitate effective delivery of thyroid disorder treatments. For example, studies show these systems improve continuity of care for thyroid patients requiring ongoing hormone therapy. Inventory optimization tools help providers manage stock of thyroid medications. Health organizations have found these systems particularly valuable in managing supplies of radioactive iodine used to treat thyroid cancer. Other applications include regulatory compliance tools, which surveys show are increasingly important as thyroid treatment guidelines evolve, and data analytics platforms that allow providers to track treatment outcomes across patient populations.

Segments

Based on Type

Manually Managed Inventory Systems
Barcode Scanning Systems
Advanced Radio Frequency Identification (RFID) Systems

Based on Application

Order Management
Asset Tracking
Service Management
Inventory Optimization
Others

Based on End Users

Traditional Retailers
Off-price Retailers

Based on Deployment

On-demand
On-premise

Based on Region

North America
- US
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- South Korea
- South-east Asia
- Rest of Asia Pacific
Latin America
- Brazil
- Argentina
- Rest of Latin America
Middle East & Africa
- GCC Countries
- South Africa
- Rest of Middle East and Africa

Regional Analysis

North America (45%):

North America holds the largest market share in the global thyroid gland disorder treatment market, accounting for approximately 45%. This dominant position is attributed to the region’s advanced healthcare infrastructure, high levels of investment in medical research and development, and robust regulatory frameworks. Government surveys indicate a significant prevalence of thyroid disorders in the adult population. For instance, data from national health surveys show that a substantial portion of adults have some form of thyroid dysfunction, with many cases remaining undiagnosed. The United States and Canada benefit from well-established healthcare systems and a high rate of thyroid disorder diagnosis, which drives demand for both conventional and innovative treatment options. Health authority reports highlight increasing awareness and screening programs that have led to earlier detection and treatment of thyroid conditions across North America.

Europe (30%):

Europe follows North America with a market share of around 30%. The European market is characterized by a strong healthcare infrastructure and significant government investment in healthcare services. National health surveys across European countries reveal varying but generally high rates of thyroid disorders, particularly in iodine-deficient regions. For instance, government data from countries like Germany and the UK show that thyroid dysfunction affects a considerable percentage of the adult population, with higher prevalence in women and older age groups. Countries such as Germany, France, and the United Kingdom have well-established treatment protocols and advanced diagnostic technologies, which enhance patient care and treatment outcomes. European health authorities have conducted extensive studies on the impact of iodine fortification programs, showing improvements in population thyroid health in many areas.

Key players

Abbott
AbbVie, Inc.
Lannett
GlaxoSmithKline plc
Pfizer, Inc.
Amgen Inc.
Merck KGaA
Mylan N.V

Competitive Analysis

The global thyroid gland disorder treatment market features a competitive landscape dominated by several key players, each leveraging their strengths to capture market share. Abbott and AbbVie, Inc. are prominent for their innovative drug formulations and extensive research capabilities. Lannett and Mylan N.V. focus on affordable generic alternatives, enhancing accessibility to treatments. GlaxoSmithKline plc and Pfizer, Inc. bring significant resources and advanced therapeutic solutions to the market, driving innovation and improving patient outcomes. Amgen Inc. and Merck KGaA contribute through their specialized biopharmaceuticals and cutting-edge research. Competitive strategies among these players include expanding product portfolios, investing in R&D, and pursuing strategic collaborations to address emerging treatment needs and enhance market positioning.

Recent Developments

In February 2024, AbbVie completed the acquisition of ImmunoGen, expanding its oncology portfolio. While not directly related to thyroid disorders, this acquisition strengthens AbbVie’s position in the broader pharmaceutical market.
In July 2020, Lannett Company, Inc. entered into an exclusive distribution agreement with Cediprof for FDA-approved Levothyroxine, a critical medication for thyroid deficiency. This agreement was set to commence on August 3, 2020, with a 10-year exclusive supply and distribution agreement starting from July 31, 2022.
In August 2024, GlaxoSmithKline plc (GSK) reported strong performance across its portfolio, including in Specialty Medicines. While not specific to thyroid disorders, this growth indicates the company’s overall strength in the pharmaceutical market.
In April 2024, Amgen announced the imminent submission of a Marketing Authorization Application to the European Medicines Agency for teprotumumab, a treatment for moderate to severe Thyroid Eye Disease (TED) in adults. This represents a significant development in thyroid-related treatments.

Market Concentration and Characteristics

The global thyroid gland disorder treatment market exhibits moderate to high market concentration, characterized by a few major players holding substantial shares, while also featuring a diverse range of companies contributing to market dynamics. The market is dominated by well-established pharmaceutical companies such as Abbott, AbbVie, GlaxoSmithKline plc, and Pfizer, which leverage their extensive R&D capabilities, broad product portfolios, and global distribution networks to maintain a competitive edge. Concurrently, the presence of companies specializing in generics like Mylan N.V. and Lannett provides cost-effective treatment alternatives, increasing market accessibility. This blend of large, innovative firms and nimble, specialized players fosters a competitive environment driven by advancements in treatment options, technological innovation, and strategic collaborations. The market is further characterized by a focus on personalized medicine and increasing investment in research and development to address the growing prevalence of thyroid disorders and enhance patient outcomes.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Report Coverage

The research report offers an in-depth analysis based on Type, Application, End Users, Deployment and Region. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook

The global thyroid gland disorder treatment market is expected to see significant growth in personalized medicine, with tailored therapies based on genetic profiles becoming more prevalent. This approach will enhance treatment efficacy and patient outcomes.
Continued advancements in diagnostic technologies, such as molecular diagnostics and advanced imaging, will improve early detection and accurate diagnosis of thyroid disorders. Enhanced diagnostics will drive market growth by facilitating timely and effective interventions.
Pharmaceutical companies are likely to increase investment in developing novel and targeted therapies for thyroid disorders. New drug formulations and delivery systems will cater to unmet needs and improve patient management.
The increasing prevalence of thyroid disorders, driven by lifestyle changes and environmental factors, will fuel demand for innovative treatment options. This trend will contribute to sustained market expansion and innovation.
Emerging markets in Asia-Pacific, Latin America, and the Middle East & Africa will experience substantial growth due to improving healthcare infrastructure and rising patient awareness. These regions present significant opportunities for market expansion.
The integration of digital health technologies, such as telemedicine and remote monitoring tools, will enhance patient access and management of thyroid disorders. This trend will drive efficiency and convenience in treatment delivery.
Rising healthcare expenditure globally will support the development and adoption of advanced treatment options for thyroid disorders. Increased funding for healthcare will enable broader access to cutting-edge therapies.
Evolving regulatory policies and healthcare reforms will impact market dynamics by influencing drug approval processes and treatment standards. Adaptation to these changes will be crucial for market participants.
There will be a growing emphasis on preventive care and early intervention strategies for thyroid disorders. Public health initiatives and educational programs will drive awareness and facilitate early diagnosis.
Strategic collaborations, partnerships, and mergers among pharmaceutical companies and research institutions will accelerate innovation and market growth. These alliances will enhance R&D capabilities and expand market reach.

CHAPTER NO. 1 : INTRODUCTION 20
1.1.1. Report Description 20
Purpose of the Report 20
USP & Key Offerings 20
1.1.2. Key Benefits for Stakeholders 20
1.1.3. Target Audience 21
1.1.4. Report Scope 21
CHAPTER NO. 2 : EXECUTIVE SUMMARY 22
2.1. Thyroid Gland Disorder Treatment Market Snapshot 22
2.1.1. Global Thyroid Gland Disorder Treatment Market, 2018 – 2032 (USD Million) 23
CHAPTER NO. 3 : GEOPOLITICAL CRISIS IMPACT ANALYSIS 24
3.1. Russia-Ukraine and Israel-Palestine War Impacts 24
CHAPTER NO. 4 : THYROID GLAND DISORDER TREATMENT MARKET – INDUSTRY ANALYSIS 25
4.1. Introduction 25
4.2. Market Drivers 26
4.2.1. Driving Factor 1 Analysis 26
4.2.2. Driving Factor 2 Analysis 27
4.3. Market Restraints 28
4.3.1. Restraining Factor Analysis 28
4.4. Market Opportunities 29
4.4.1. Market Opportunity Analysis 29
4.5. Porter’s Five Forces Analysis 30
CHAPTER NO. 5 : ANALYSIS COMPETITIVE LANDSCAPE 31
5.1. Company Market Share Analysis – 2023 31
5.1.1. Global Thyroid Gland Disorder Treatment Market: Company Market Share, by Volume, 2023 31
5.1.2. Global Thyroid Gland Disorder Treatment Market: Company Market Share, by Revenue, 2023 32
5.1.3. Global Thyroid Gland Disorder Treatment Market: Top 6 Company Market Share, by Revenue, 2023 32
5.1.4. Global Thyroid Gland Disorder Treatment Market: Top 3 Company Market Share, by Revenue, 2023 33
5.2. Global Thyroid Gland Disorder Treatment Market Company Revenue Market Share, 2023 34
5.3. Company Assessment Metrics, 2023 35
5.3.1. Stars 35
5.3.2. Emerging Leaders 35
5.3.3. Pervasive Players 35
5.3.4. Participants 35
5.4. Start-ups /SMEs Assessment Metrics, 2023 35
5.4.1. Progressive Companies 35
5.4.2. Responsive Companies 35
5.4.3. Dynamic Companies 35
5.4.4. Starting Blocks 35
5.5. Strategic Developments 36
5.5.1. Acquisitions & Mergers 36
New Product Launch 36
Global Expansion 36
5.6. Key Players Product Matrix 37
CHAPTER NO. 6 : PESTEL & ADJACENT MARKET ANALYSIS 38
6.1. PESTEL 38
6.1.1. Political Factors 38
6.1.2. Economic Factors 38
6.1.3. Social Factors 38
6.1.4. Technological Factors 38
6.1.5. Environmental Factors 38
6.1.6. Legal Factors 38
6.2. Adjacent Market Analysis 38
CHAPTER NO. 7 : THYROID GLAND DISORDER TREATMENT MARKET – BY INDICATION SEGMENT ANALYSIS 39
7.1. Thyroid Gland Disorder Treatment Market Overview, by Indication Segment 39
7.1.1. Thyroid Gland Disorder Treatment Market Revenue Share, By Indication, 2023 & 2032 40
7.1.2. Thyroid Gland Disorder Treatment Market Attractiveness Analysis, By Indication 41
7.1.3. Incremental Revenue Growth Opportunity, by Indication, 2024 – 2032 41
7.1.4. Thyroid Gland Disorder Treatment Market Revenue, By Indication, 2018, 2023, 2027 & 2032 42
7.2. Hypothyroidism 43
7.3. Hyperthyroidism 44
CHAPTER NO. 8 : THYROID GLAND DISORDER TREATMENT MARKET – BY ROUTE OF ADMINISTRATION SEGMENT ANALYSIS 45
8.1. Thyroid Gland Disorder Treatment Market Overview, by Route of Administration Segment 45
8.1.1. Thyroid Gland Disorder Treatment Market Revenue Share, By Route of Administration, 2023 & 2032 46
8.1.2. Thyroid Gland Disorder Treatment Market Attractiveness Analysis, By Route of Administration 47
8.1.3. Incremental Revenue Growth Opportunity, by Route of Administration, 2024 – 2032 47
8.1.4. Thyroid Gland Disorder Treatment Market Revenue, By Route of Administration, 2018, 2023, 2027 & 2032 48
8.2. Oral 49
8.3. Intravenous 50
8.4. Others 51
CHAPTER NO. 9 : THYROID GLAND DISORDER TREATMENT MARKET – BY DISTRIBUTION CHANNEL SEGMENT ANALYSIS 52
9.1. Thyroid Gland Disorder Treatment Market Overview, by Distribution Channel Segment 52
9.1.1. Thyroid Gland Disorder Treatment Market Revenue Share, By Distribution Channel, 2023 & 2032 53
9.1.2. Thyroid Gland Disorder Treatment Market Attractiveness Analysis, By Distribution Channel 54
9.1.3. Incremental Revenue Growth Opportunity, by Distribution Channel, 2024 – 2032 54
9.1.4. Thyroid Gland Disorder Treatment Market Revenue, By Distribution Channel, 2018, 2023, 2027 & 2032 55
9.2. Wholesalers/Distributors 56
9.3. Retail Chain 57
9.4. Online Distribution 58
9.5. Others 59
CHAPTER NO. 10 : THYROID GLAND DISORDER TREATMENT MARKET – GLOBAL ANALYSIS 60
10.1. Indication 60
10.1.1. Global Thyroid Gland Disorder Treatment Market Revenue, By Indication, 2018 – 2023 (USD Million) 60
10.1.2. Global Thyroid Gland Disorder Treatment Market Revenue, By Indication, 2024 – 2032 (USD Million) 60
10.2. Route of Administration 61
10.2.1. Global Thyroid Gland Disorder Treatment Market Revenue, By Route of Administration, 2018 – 2023 (USD Million) 61
10.2.2. Global Thyroid Gland Disorder Treatment Market Revenue, By Route of Administration, 2024 – 2032 (USD Million) 61
10.3. Distribution Channel 62
10.3.1. Global Thyroid Gland Disorder Treatment Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 62
10.3.2. Global Thyroid Gland Disorder Treatment Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 62
CHAPTER NO. 11 : THYROID GLAND DISORDER TREATMENT MARKET – NORTH AMERICA 63
11.1. North America 63
11.1.1. Key Highlights 63
11.1.2. North America Thyroid Gland Disorder Treatment Market Revenue, By Country, 2018 – 2023 (USD Million) 64
11.1.3. North America Thyroid Gland Disorder Treatment Market Revenue, By Indication, 2018 – 2023 (USD Million) 65
11.1.4. North America Thyroid Gland Disorder Treatment Market Revenue, By Route of Administration, 2018 – 2023 (USD Million) 66
11.1.5. North America Thyroid Gland Disorder Treatment Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 67
11.2. U.S. 68
11.3. Canada 68
11.4. Mexico 68
CHAPTER NO. 12 : THYROID GLAND DISORDER TREATMENT MARKET – EUROPE 69
12.1. Europe 69
12.1.1. Key Highlights 69
12.1.2. Europe Thyroid Gland Disorder Treatment Market Revenue, By Country, 2018 – 2023 (USD Million) 70
12.1.3. Europe Thyroid Gland Disorder Treatment Market Revenue, By Indication, 2018 – 2023 (USD Million) 71
12.1.4. Europe Thyroid Gland Disorder Treatment Market Revenue, By Route of Administration, 2018 – 2023 (USD Million) 72
12.1.5. Europe Thyroid Gland Disorder Treatment Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 73
12.2. UK 74
12.3. France 74
12.4. Germany 74
12.5. Italy 74
12.6. Spain 74
12.7. Russia 74
12.8. Belgium 74
12.9. Netherland 74
12.10. Austria 74
12.11. Sweden 74
12.12. Poland 74
12.13. Denmark 74
12.14. Switzerland 74
12.15. Rest of Europe 74
CHAPTER NO. 13 : THYROID GLAND DISORDER TREATMENT MARKET – ASIA PACIFIC 75
13.1. Asia Pacific 75
13.1.1. Key Highlights 75
13.1.2. Asia Pacific Thyroid Gland Disorder Treatment Market Revenue, By Country, 2018 – 2023 (USD Million) 76
13.1.3. Asia Pacific Thyroid Gland Disorder Treatment Market Revenue, By Indication, 2018 – 2023 (USD Million) 77
13.1.4. Asia Pacific Thyroid Gland Disorder Treatment Market Revenue, By Route of Administration, 2018 – 2023 (USD Million) 78
13.1.5. Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 79
13.2. China 80
13.3. Japan 80
13.4. South Korea 80
13.5. India 80
13.6. Australia 80
13.7. Thailand 80
13.8. Indonesia 80
13.9. Vietnam 80
13.10. Malaysia 80
13.11. Philippines 80
13.12. Taiwan 80
13.13. Rest of Asia Pacific 80
CHAPTER NO. 14 : THYROID GLAND DISORDER TREATMENT MARKET – LATIN AMERICA 81
14.1. Latin America 81
14.1.1. Key Highlights 81
14.1.2. Latin America Thyroid Gland Disorder Treatment Market Revenue, By Country, 2018 – 2023 (USD Million) 82
14.1.3. Latin America Thyroid Gland Disorder Treatment Market Revenue, By Indication, 2018 – 2023 (USD Million) 83
14.1.4. Latin America Thyroid Gland Disorder Treatment Market Revenue, By Route of Administration, 2018 – 2023 (USD Million) 84
14.1.5. Latin America Thyroid Gland Disorder Treatment Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 85
14.2. Brazil 86
14.3. Argentina 86
14.4. Peru 86
14.5. Chile 86
14.6. Colombia 86
14.7. Rest of Latin America 86
CHAPTER NO. 15 : THYROID GLAND DISORDER TREATMENT MARKET – MIDDLE EAST 87
15.1. Middle East 87
15.1.1. Key Highlights 87
15.1.2. Middle East Thyroid Gland Disorder Treatment Market Revenue, By Country, 2018 – 2023 (USD Million) 88
15.1.3. Middle East Thyroid Gland Disorder Treatment Market Revenue, By Indication, 2018 – 2023 (USD Million) 89
15.1.4. Middle East Thyroid Gland Disorder Treatment Market Revenue, By Route of Administration, 2018 – 2023 (USD Million) 90
15.1.5. Middle East Thyroid Gland Disorder Treatment Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 91
15.2. UAE 92
15.3. KSA 92
15.4. Israel 92
15.5. Turkey 92
15.6. Iran 92
15.7. Rest of Middle East 92
CHAPTER NO. 16 : THYROID GLAND DISORDER TREATMENT MARKET – AFRICA 93
16.1. Africa 93
16.1.1. Key Highlights 93
16.1.2. Africa Thyroid Gland Disorder Treatment Market Revenue, By Country, 2018 – 2023 (USD Million) 94
16.1.3. Africa Thyroid Gland Disorder Treatment Market Revenue, By Indication, 2018 – 2023 (USD Million) 95
16.1.4. Africa Thyroid Gland Disorder Treatment Market Revenue, By Route of Administration, 2018 – 2023 (USD Million) 96
16.1.5. Africa Thyroid Gland Disorder Treatment Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 97
16.2. Egypt 98
16.3. Nigeria 98
16.4. Algeria 98
16.5. Morocco 98
16.6. Rest of Africa 98
CHAPTER NO. 17 : COMPANY PROFILES 99
17.1. Abbott 99
17.1.1. Company Overview 99
17.1.2. Product Portfolio 99
17.1.3. Swot Analysis 99
17.1.4. Business Strategy 100
17.1.5. Financial Overview 100
17.2. AbbVie, Inc. 101
17.3. Lannett Company, Inc. 101
17.4. GlaxoSmithKline plc. 101
17.5. Pfizer, Inc. 101
17.6. Amgen Inc. 101
17.7. Merck KGaA. 101
17.8. Mylan N.V. 101
CHAPTER NO. 18 : RESEARCH METHODOLOGY 102
18.1. Research Methodology 102
18.1.1. Phase I – Secondary Research 103
18.1.2. Phase II – Data Modeling 103
Company Share Analysis Model 104
Revenue Based Modeling 104
18.1.3. Phase III – Primary Research 105
18.1.4. Research Limitations 106
Assumptions 106

List of Figures
FIG NO. 1. Global Thyroid Gland Disorder Treatment Market Revenue, 2018 – 2032 (USD Million) 23
FIG NO. 2. Porter’s Five Forces Analysis for Global Thyroid Gland Disorder Treatment Market 30
FIG NO. 3. Company Share Analysis, 2023 31
FIG NO. 4. Company Share Analysis, 2023 32
FIG NO. 5. Company Share Analysis, 2023 32
FIG NO. 6. Company Share Analysis, 2023 33
FIG NO. 7. Thyroid Gland Disorder Treatment Market – Company Revenue Market Share, 2023 34
FIG NO. 8. Thyroid Gland Disorder Treatment Market Revenue Share, By Indication, 2023 & 2032 40
FIG NO. 9. Market Attractiveness Analysis, By Indication 41
FIG NO. 10. Incremental Revenue Growth Opportunity by Indication, 2024 – 2032 41
FIG NO. 11. Thyroid Gland Disorder Treatment Market Revenue, By Indication, 2018, 2023, 2027 & 2032 42
FIG NO. 12. Global Thyroid Gland Disorder Treatment Market for Hypothyroidism, Revenue (USD Million) 2018 – 2032 43
FIG NO. 13. Global Thyroid Gland Disorder Treatment Market for Hyperthyroidism, Revenue (USD Million) 2018 – 2032 44
FIG NO. 14. Thyroid Gland Disorder Treatment Market Revenue Share, By Route of Administration, 2023 & 2032 46
FIG NO. 15. Market Attractiveness Analysis, By Route of Administration 47
FIG NO. 16. Incremental Revenue Growth Opportunity by Route of Administration, 2024 – 2032 47
FIG NO. 17. Thyroid Gland Disorder Treatment Market Revenue, By Route of Administration, 2018, 2023, 2027 & 2032 48
FIG NO. 18. Global Thyroid Gland Disorder Treatment Market for Oral, Revenue (USD Million) 2018 – 2032 49
FIG NO. 19. Global Thyroid Gland Disorder Treatment Market for Intravenous, Revenue (USD Million) 2018 – 2032 50
FIG NO. 20. Global Thyroid Gland Disorder Treatment Market for Others, Revenue (USD Million) 2018 – 2032 51
FIG NO. 21. Thyroid Gland Disorder Treatment Market Revenue Share, By Distribution Channel, 2023 & 2032 53
FIG NO. 22. Market Attractiveness Analysis, By Distribution Channel 54
FIG NO. 23. Incremental Revenue Growth Opportunity by Distribution Channel, 2024 – 2032 54
FIG NO. 24. Thyroid Gland Disorder Treatment Market Revenue, By Distribution Channel, 2018, 2023, 2027 & 2032 55
FIG NO. 25. Global Thyroid Gland Disorder Treatment Market for Wholesalers/Distributors, Revenue (USD Million) 2018 – 2032 56
FIG NO. 26. Global Thyroid Gland Disorder Treatment Market for Retail Chain, Revenue (USD Million) 2018 – 2032 57
FIG NO. 27. Global Thyroid Gland Disorder Treatment Market for Online Distribution, Revenue (USD Million) 2018 – 2032 58
FIG NO. 28. Global Thyroid Gland Disorder Treatment Market for Others, Revenue (USD Million) 2018 – 2032 59
FIG NO. 29. North America Thyroid Gland Disorder Treatment Market Revenue, 2018 – 2032 (USD Million) 63
FIG NO. 30. Europe Thyroid Gland Disorder Treatment Market Revenue, 2018 – 2032 (USD Million) 69
FIG NO. 31. Asia Pacific Thyroid Gland Disorder Treatment Market Revenue, 2018 – 2032 (USD Million) 75
FIG NO. 32. Latin America Thyroid Gland Disorder Treatment Market Revenue, 2018 – 2032 (USD Million) 81
FIG NO. 33. Middle East Thyroid Gland Disorder Treatment Market Revenue, 2018 – 2032 (USD Million) 87
FIG NO. 34. Africa Thyroid Gland Disorder Treatment Market Revenue, 2018 – 2032 (USD Million) 93
FIG NO. 35. Research Methodology – Detailed View 102
FIG NO. 36. Research Methodology 103

List of Tables
TABLE NO. 1. : Global Thyroid Gland Disorder Treatment Market: Snapshot 22
TABLE NO. 2. : Drivers for the Thyroid Gland Disorder Treatment Market: Impact Analysis 26
TABLE NO. 3. : Restraints for the Thyroid Gland Disorder Treatment Market: Impact Analysis 28
TABLE NO. 4. : Global Thyroid Gland Disorder Treatment Market Revenue, By Indication, 2018 – 2023 (USD Million) 60
TABLE NO. 5. : Global Thyroid Gland Disorder Treatment Market Revenue, By Indication, 2024 – 2032 (USD Million) 60
TABLE NO. 6. : Global Thyroid Gland Disorder Treatment Market Revenue, By Route of Administration, 2018 – 2023 (USD Million) 61
TABLE NO. 7. : Global Thyroid Gland Disorder Treatment Market Revenue, By Route of Administration, 2024 – 2032 (USD Million) 61
TABLE NO. 8. : Global Thyroid Gland Disorder Treatment Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 62
TABLE NO. 9. : Global Thyroid Gland Disorder Treatment Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 62
TABLE NO. 10. : North America Thyroid Gland Disorder Treatment Market Revenue, By Country, 2018 – 2023 (USD Million) 64
TABLE NO. 11. : North America Thyroid Gland Disorder Treatment Market Revenue, By Country, 2024 – 2032 (USD Million) 64
TABLE NO. 12. : North America Thyroid Gland Disorder Treatment Market Revenue, By Indication, 2018 – 2023 (USD Million) 65
TABLE NO. 13. : North America Thyroid Gland Disorder Treatment Market Revenue, By Indication, 2024 – 2032 (USD Million) 65
TABLE NO. 14. : North America Thyroid Gland Disorder Treatment Market Revenue, By Route of Administration, 2018 – 2023 (USD Million) 66
TABLE NO. 15. : North America Thyroid Gland Disorder Treatment Market Revenue, By Route of Administration, 2024 – 2032 (USD Million) 66
TABLE NO. 16. : North America Thyroid Gland Disorder Treatment Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 67
TABLE NO. 17. : North America Thyroid Gland Disorder Treatment Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 67
TABLE NO. 18. : Europe Thyroid Gland Disorder Treatment Market Revenue, By Country, 2018 – 2023 (USD Million) 70
TABLE NO. 19. : Europe Thyroid Gland Disorder Treatment Market Revenue, By Country, 2024 – 2032 (USD Million) 70
TABLE NO. 20. : Europe Thyroid Gland Disorder Treatment Market Revenue, By Indication, 2018 – 2023 (USD Million) 71
TABLE NO. 21. : Europe Thyroid Gland Disorder Treatment Market Revenue, By Indication, 2024 – 2032 (USD Million) 71
TABLE NO. 22. : Europe Thyroid Gland Disorder Treatment Market Revenue, By Route of Administration, 2018 – 2023 (USD Million) 72
TABLE NO. 23. : Europe Thyroid Gland Disorder Treatment Market Revenue, By Route of Administration, 2024 – 2032 (USD Million) 72
TABLE NO. 24. : Europe Thyroid Gland Disorder Treatment Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 73
TABLE NO. 25. : Europe Thyroid Gland Disorder Treatment Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 73
TABLE NO. 26. : Asia Pacific Thyroid Gland Disorder Treatment Market Revenue, By Country, 2018 – 2023 (USD Million) 76
TABLE NO. 27. : Asia Pacific Thyroid Gland Disorder Treatment Market Revenue, By Country, 2024 – 2032 (USD Million) 76
TABLE NO. 28. : Asia Pacific Thyroid Gland Disorder Treatment Market Revenue, By Indication, 2018 – 2023 (USD Million) 77
TABLE NO. 29. : Asia Pacific Thyroid Gland Disorder Treatment Market Revenue, By Indication, 2024 – 2032 (USD Million) 77
TABLE NO. 30. : Asia Pacific Thyroid Gland Disorder Treatment Market Revenue, By Route of Administration, 2018 – 2023 (USD Million) 78
TABLE NO. 31. : Asia Pacific Thyroid Gland Disorder Treatment Market Revenue, By Route of Administration, 2024 – 2032 (USD Million) 78
TABLE NO. 32. : Asia Pacific Thyroid Gland Disorder Treatment Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 79
TABLE NO. 33. : Asia Pacific Thyroid Gland Disorder Treatment Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 79
TABLE NO. 34. : Latin America Thyroid Gland Disorder Treatment Market Revenue, By Country, 2018 – 2023 (USD Million) 82
TABLE NO. 35. : Latin America Thyroid Gland Disorder Treatment Market Revenue, By Country, 2024 – 2032 (USD Million) 82
TABLE NO. 36. : Latin America Thyroid Gland Disorder Treatment Market Revenue, By Indication, 2018 – 2023 (USD Million) 83
TABLE NO. 37. : Latin America Thyroid Gland Disorder Treatment Market Revenue, By Indication, 2024 – 2032 (USD Million) 83
TABLE NO. 38. : Latin America Thyroid Gland Disorder Treatment Market Revenue, By Route of Administration, 2018 – 2023 (USD Million) 84
TABLE NO. 39. : Latin America Thyroid Gland Disorder Treatment Market Revenue, By Route of Administration, 2024 – 2032 (USD Million) 84
TABLE NO. 40. : Latin America Thyroid Gland Disorder Treatment Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 85
TABLE NO. 41. : Latin America Thyroid Gland Disorder Treatment Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 85
TABLE NO. 42. : Middle East Thyroid Gland Disorder Treatment Market Revenue, By Country, 2018 – 2023 (USD Million) 88
TABLE NO. 43. : Middle East Thyroid Gland Disorder Treatment Market Revenue, By Country, 2024 – 2032 (USD Million) 88
TABLE NO. 44. : Middle East Thyroid Gland Disorder Treatment Market Revenue, By Indication, 2018 – 2023 (USD Million) 89
TABLE NO. 45. : Middle East Thyroid Gland Disorder Treatment Market Revenue, By Indication, 2024 – 2032 (USD Million) 89
TABLE NO. 46. : Middle East Thyroid Gland Disorder Treatment Market Revenue, By Route of Administration, 2018 – 2023 (USD Million) 90
TABLE NO. 47. : Middle East Thyroid Gland Disorder Treatment Market Revenue, By Route of Administration, 2024 – 2032 (USD Million) 90
TABLE NO. 48. : Middle East Thyroid Gland Disorder Treatment Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 91
TABLE NO. 49. : Middle East Thyroid Gland Disorder Treatment Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 91
TABLE NO. 50. : Africa Thyroid Gland Disorder Treatment Market Revenue, By Country, 2018 – 2023 (USD Million) 94
TABLE NO. 51. : Africa Thyroid Gland Disorder Treatment Market Revenue, By Country, 2024 – 2032 (USD Million) 94
TABLE NO. 52. : Africa Thyroid Gland Disorder Treatment Market Revenue, By Indication, 2018 – 2023 (USD Million) 95
TABLE NO. 53. : Africa Thyroid Gland Disorder Treatment Market Revenue, By Indication, 2024 – 2032 (USD Million) 95
TABLE NO. 54. : Africa Thyroid Gland Disorder Treatment Market Revenue, By Route of Administration, 2018 – 2023 (USD Million) 96
TABLE NO. 55. : Africa Thyroid Gland Disorder Treatment Market Revenue, By Route of Administration, 2024 – 2032 (USD Million) 96
TABLE NO. 56. : Africa Thyroid Gland Disorder Treatment Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 97
TABLE NO. 57. : Africa Thyroid Gland Disorder Treatment Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 97

Frequently Asked Questions:

What is the projected growth of the global thyroid gland disorder treatment market?

The market is projected to grow from USD 2,389.71 million in 2023 to USD 3,386.61 million by 2032, reflecting a CAGR of 3.95% from 2024 to 2032.

What are the key drivers of the thyroid disorder treatment market?

Key drivers include the increasing prevalence of thyroid disorders, advancements in treatment modalities, and the rising adoption of personalized medicine and innovative technologies.

Which regions are leading in the thyroid disorder treatment market?

North America holds the largest market share at approximately 45%, followed by Europe at 30%. Significant growth is also observed in the Asia-Pacific region due to improving healthcare infrastructure.

Who are the major players in the thyroid disorder treatment market?

Major players include Abbott, AbbVie, Inc., Lannett, GlaxoSmithKline plc, Pfizer, Inc., Amgen Inc., Merck KGaA, and Mylan N.V.

What are some current trends influencing the thyroid disorder treatment market?

Current trends include the emergence of personalized medicine and targeted therapies, and the integration of digital health technologies like telemedicine and remote monitoring tools.

Purchase Options

Single User

$4699

Multi User

$5699

Custom Report

$7699

Request Free Sample

Have a question?

Don’t settle for less – trust Mitul to help you find the best solution.

Call: +91 6232 49 3207

EMAIL MITUL

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –